Thieler Law Corp, member of the Investor Attorney Network, is investigating whether members of the board of directors of Sequenom Inc (NASDAQ: SQNM) acted responsibly on behalf of investors’ profitability in the planned $371 million sale to Laboratory Corporation of America Holdings.

On July 27, 2016, Sequenom Inc (NASDAQ: SQNM) and Laboratory Corporation of America Holdings announced that they had entered into a merger agreement. Under the terms of the merger agreement, Laboratory Corporation will offer Sequenom shareholders $2.40 per share in cash for all outstanding shares.    

Based in San Diego, CA, and founded in 1994 Sequenom Inc develops and commercializes molecular diagnostics testing services for the women's health and oncology markets.

The investigation focuses on whether NASDAQ: SQNM investors received the highest price and whether the directors of Sequenom Inc acted in the best interest of Sequenom Inc company and its shareholders.   

If you purchased Sequenom Inc (NASDAQ: SQNM) prior to July 27, 2016, you should contact Thieler Law Corp at mail@thielerlaw.com or call +1 (619) 377 - 4324.

Thieler Law Corp

2534 State Street - Suite 406,

San Diego, CA 92101

by

email: mail@thielerlaw.com 

or

telephone at +1 (619) 377 - 4324

or

visit our website http://www.thielerlaw.com/ 

or

Facsimile: +1 (619) 785 – 3185